Vectura Group

Founded in 1997, Vectura manufactures inhalers and nebulizers that allow patients to inhale medicine as an aerosol through a mouthpiece or mask. Among the customers of the company can be called Novartis and GlaxoSmithKline (by July 2021).

History

2021: Philip Morris bought a developer of inhalation devices for $1.5 billion

In mid-July 2021, Philip Morris acquired the British asthma drug manufacturer Vectura Group for $1.5 billion. Vectura employs more than 200 scientists with experience in the development of formulations and inhalation devices, as well as their clinical production.

It is known that Philip Morris has already invested more than $8 billion in the development of alternatives to smoking, such as IQOS, which has become one of the products most popular among smokers. Earlier in July 2021, Philip Morris announced the acquisition of Fertin Pharma, a manufacturer of nicotine chewing gum and oral painkillers, for $820 million. Other products developed by the company are aimed at increasing vigor or helping with falling asleep. The cigarette manufacturer predicts that one day it will simply stop selling a product that once brought it to a leading position in the world.

Philip Morris bought a developer of inhalation devices for $1.5 billion

Since 2012, the total sales of 13 Vectura inhalation drugs on the market amounted to more than $11 billion. Philip Morris wants Vectura to continue working with its pharmaceutical customers and to develop new products in collaboration with Philip Morris.

Fertin and Vectura allow us to quickly double the number of company products on the market. If we developed these products and products on our own, we would cope, but would lose time. And we cannot afford this, "explained Philip Morris Chief Executive Officer Jacek Olczak[1]

Notes